After Gummies: The Next Cannabis Format to Watch

Photo by elsaolofsson via Pixabay.

You eat a gummy, check the clock, and wait. Forty minutes in, nothing. At the hour mark you start to doubt the label, so you eat a second one. Ninety minutes after that, the first dose finally arrives and the second is right behind it.

Most people who use edibles have lived some version of this, and the gap between swallowing and feeling is the opening for whatever format comes next.

A caution before we go further. This is a forecast built on pharmacology and precedent. Current category-share data was not available when this piece was assembled, so I will not quote sales figures I cannot verify.

My claim is modest. The next winner is probably less a gummy replacement than a faster, more precise and more discreet format that takes share at the margins. It would grow by fixing the wait-and-guess problem, and gummies would keep their core buyers.

What a Plateau Would Actually Look Like

Start with an honest caveat. Edibles may be plateauing, but I have not confirmed that against Headset and BDSA category-share data for Q3 2026, and anyone republishing this should check those numbers first. What follows treats a plateau as a working hypothesis, not a measured fact.

In practice, a plateau would show up as four things together:

• A flat share of category dollars.
• Falling price per milligram of THC.
• Shelves crowded with near-identical gummies in different wrappers.
• Shrinking novelty, where a new flavor no longer moves anyone.

Gummies became the default for understandable reasons. The format is familiar candy. There is no combustion, so no smell, no lighter, no cough. Per-piece dosing is easy to explain, and a first-time buyer can pick up a 5 mg piece without learning any gear.

Those same strengths are why the format is now crowded. A low barrier to entry for buyers is also a low barrier for manufacturers.

One vendor prediction piece, from kayapush.com, anticipates growth in functional blends that pair cannabinoids with adaptogens and terpenes, and in pre-rolls infused with minor cannabinoids. Treat that as an industry prediction. It cites no data, dates or named sources, so it counts as a hint about where marketers are looking, not as evidence.

A note on how to read this article. Statements about liver metabolism, approval history and onset times are established fact, and I will say so. Statements beginning with phrases like if that pattern holds are reasoned extrapolation. Anything labeled speculative is a guess, offered because it is useful to think about, not because the evidence supports it yet.

The Pharmacological Ceiling on Gummies

The ceiling on gummies is biological. When THC is swallowed, it passes through the gut and then the liver before reaching general circulation. There, a meaningful portion converts to 11-hydroxy-THC, a metabolite that is potent and slow to build. Peer-reviewed reviews put oral THC bioavailability low, roughly 4 to 12 percent, with large variation between individuals.

Onset is commonly 30 to 120 minutes, and effects can last for hours. That is established, and it explains a great deal. The spread in onset is why a person can feel nothing at the hour mark and then be overwhelmed at hour two. It is also why regulators cap serving sizes and why overconsumption stories are so familiar.

The practical consequence is that consumers cannot titrate. Inhalation lets a person feel an effect within minutes and stop when satisfied. Eating a gummy is closer to placing a bet and waiting to see what you won.

Manufacturing adds a second layer of uncertainty. Spreading cannabinoid evenly through a gelatin or pectin batch is hard, and the result can be pieces that differ from the label. Lab testing is the pressure point here. Products that test tightly can credibly market consistency, and the ones that cannot will find it harder to hide.

Now the counter-case, and it is a real one. For sleep, chronic pain and long-duration use, slow onset and a long tail are features. Someone who wants to be asleep in ninety minutes and stay that way does not need a faster product.

So the ceiling is not a death sentence for gummies. It marks the occasions they serve badly: a social evening, a lunch break, a first try where the person wants to stop at the right amount. Those are the occasions a faster format can claim.

What Nicotine, Opioid Treatment and Alcohol Teach Us

Three precedents suggest how format shifts tend to happen. None maps perfectly onto cannabis, but together they show a pattern.

First, nicotine. Cigarettes gave way to gum, lozenges and patches as cessation tools, and later to oral pouches as an ordinary consumer product. The lesson is that discreet, smoke-free, no-prep formats win when social settings reward them. Nobody has to step outside to use a pouch.

Second, medicine. Buprenorphine-naloxone sublingual film, sold as Suboxone, was approved by the FDA in 2010 and became a mainstream delivery form. That matters here because it shows a regulator-accepted route for dissolvable films with unit dosing. A film with a defined dose is not an exotic idea to health authorities.

Third, alcohol. Ready-to-drink seltzers and canned cocktails grew by removing preparation and measurement steps. I treat this as a documented analogy for cannabis beverages, not as proof. The specifics of their growth would need checking before anyone leans on them.

From these three, here is the reasoned extrapolation. Format shifts tend to follow convenience and discretion first, with potency or novelty second. Pouches did not beat cigarettes on strength, and canned cocktails did not beat bar drinks on craft. They won by taking away a chore.

The counter-case is that cannabis lacks what helped those precedents. Nicotine had huge brand marketing and a clear federal pathway. Cannabis has fragmented state rules and tight limits on advertising, so a new format cannot be introduced to the whole country at once. If that friction holds, the timeline stretches. A one-to-three-year window may see early movers and pilot launches, not a market-wide handoff.

The Contenders: Strips, Beverages, Pre-Rolls and Beyond

Here are the candidates, compared on the four things that matter most to a buyer. The entries are qualitative judgments, not measured data.

Strips and films are unit-dosed, pocketable, carry no calories and contain no sugar. Their weakness is physical. A film can only hold so many milligrams of cannabinoid, and masking the taste of that load is a genuine formulation challenge.

Beverages offer a social-occasion format and an alcohol-replacement story. Their risks are shelf stability, taste, and distribution rules that differ by state.

Minor-cannabinoid pre-rolls, mentioned in the vendor piece, are an evolution of flower and not a new format. Whether they gain real share is unverified.

My pick for the next one to three years is oral films and strips, with sublingual tablets as a close cousin. The reason is that they fix onset and dosing without asking consumers to change habits much. You still put something in your mouth, you just stop waiting.

What would change my mind? Evidence that beverages hold a clear lead in repeat purchases, or human data showing films do not speed onset at all. Either would send me back to the table.

Bioavailability Claims: What Is Proven and What Is Marketing

Photo by Dad Grass via Pexels.

Oromucosal delivery is not new. Nabiximols, sold as Sativex, is a cannabis-based oromucosal spray approved in several countries, though not in the US. That is established, and it shows the route can work clinically.

The claim to test is different. Nanoemulsions and water-soluble formulations are marketed as faster and more bioavailable. Before stating any number, one would need peer-reviewed human pharmacokinetic studies on oral-mucosal and nanoemulsified cannabinoids. None were available when this piece was put together, so I give no figures.

The mechanism is easy to explain. Absorption through cheek or under-tongue tissue can bypass some first-pass metabolism. But most films are at least partly swallowed, so real-world results are often a blend of both routes. A product can be faster than a gummy and still be slower than an inhaled dose.

The counter-case deserves weight. Small studies funded by manufacturers, run in healthy volunteers on single doses, do not prove a consumer benefit. A convincing study would have these features:

• Independent or transparently funded design.
• A crossover comparison against a standard edible and an inhaled dose.
• Repeat dosing, including in regular users.
• Blood levels and subjective effects tracked together over time.
• Results that replicate in a second group.

Here is the open speculation, labeled as such. If strips deliver a more predictable dose, budtenders could sell them like a medicine, with guidance on starting amounts and timing. That would change who buys them, pulling in cautious older adults and curious non-users. It is a plausible path, but nothing yet demonstrates it.

The Regulatory Wildcard: Hemp THC and State Rules

Photo by Nataliya Vaitkevich via Pexels.

A flag for verification before anyone relies on this section. A federal appropriations law in November 2025 redefined hemp and restricted intoxicating hemp-derived products, with a delayed effective date roughly a year out. Confirm the exact text, the per-container THC threshold and the current status on congress.gov and fda.gov. I do not state those details here because I cannot check them.

Why it matters for formats: many beverages, gummies and strips have been sold through hemp channels outside state dispensary systems. A federal narrowing would push those products toward licensed state markets, and brands would need to decide whether they can afford to follow.

History offers a pattern. The 2018 Farm Bill opened a market faster than regulators could respond. States and Congress then tightened it. The sequence is loophole, boom, backlash, and the drivers were the same each time: product growth outran the rules. If that pattern holds, restriction is more likely than permanent tolerance.

State rules then decide what survives. Variables to watch:

• Serving size and per-package caps.
• Child-resistant and opaque packaging requirements.
• Whether films and strips are a permitted product category at all in a given state.

Three scenarios follow. In the first, the hemp channel is restricted as written. In the second, it is delayed or amended. In the third, enforcement lags and the gray market continues.

My read is that restriction hits beverages and strips hardest, since those are the formats that leaned most on hemp distribution to reach shoppers outside dispensaries. A delay would buy time but not change direction. Lagging enforcement is the scenario in which little changes, and it is the hardest to bet on.

Signposts and Opportunities Over the Next 36 Months

Over the next 36 months, a short list of signposts will tell you whether this forecast is working:

1. Quarterly category-share data for edibles, beverages and pre-rolls.
2. Named-brand strip and film launches, and whether they get reordered.
3. Peer-reviewed pharmacokinetic studies on oral-mucosal products.
4. State packaging and product-category rules.

Business openings exist, and I frame them as assumptions, not predictions. Contract manufacturing of films and dissolvables is one. Precise-dosing and taste-masking technology is another. So are compliant packaging and retail education for budtenders, since a new format needs someone to explain it at the counter.

The risks are real. Copying is easy, and price compression could squeeze thin margins quickly, as it has in gummies. Regulatory reversal could also remove a distribution channel overnight.

The forecast fails under three conditions. Edibles prove more resilient than the plateau thesis assumes. Strips stay a niche, bought by a few and ignored by most. Or federal hemp rules wipe out the channel the new formats depend on.

My advice to operators is to stay small and keep notes. Run pilot SKUs, collect sell-through and repeat-purchase data, and let those numbers, not a supplier pitch, decide whether to scale. Above all, do not build a business on unproven bioavailability claims.

If a next format wins, it will most likely win by solving the wait-and-guess problem, not by being stronger. Faster, more predictable onset beats a higher milligram count for most occasions. That makes this as much a design problem as a chemistry one: dose size, taste, packaging and the moment of use all matter.

Treat every format forecast, this one included, as a hypothesis. Test it against category-share data and human studies, and revisit it when those arrive. If the numbers say gummies are holding firm, believe the numbers.

Browse our seed collection.